The activity of cefmenoxime (SCE-1365), 7,8-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]ceph-3-em-4-carboxylic acid, was compared with that of other cephalosporins. Cefinenoxime exhibited high activity against a wide variety of gram-positive and gramnegative bacteria. The in vitro activity of cefmenoxime against Streptococcus pyogenes, Haemophilus influenzae, and Enterobacteriaceae, including indolepositive Proteus, Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii, was 10 to 1,000 times greater than that of several other cephalosporins. Against Pseudomonas aeruginosa, cefmenoxime showed activity two to four times that of sulbenicillin and carbenicillin but less than that of cefsulodin. Variation in pH, addition of horse serum, and type of growth medium had definite effects on the activity of cefmenoxime, and the inoculum size affected the activity against bacterial species. In Escherichia coli cefmenoxime showed marked affinity for penicillin-binding protein 3 (PBP-3), followed by PBP-1 (1A and 1B). This affinity profile was well correlated with its filamentous cell-forming activity under extremely low drug concentrations and with its bactericidal activity against microorganisms. The high in vitro activity of cefmenoxime was reflected in the degree of protection observed in mice infected intraperitoneally with a wide variety of gram-positive and gram-negative bacteria. Furthermore, cefmenoxime showed good therapeutic activity against infection models in mice such as respiratory tract infection caused by Klebsiellapneumoniae and urinary tract infection caused by Proteus mirabilis.
The activity of cefmenoxime (SCE-1365), 7,8-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]ceph-3-em-4-carboxylic acid, was compared with that of other cephalosporins. Cefinenoxime exhibited high activity against a wide variety of gram-positive and gramnegative bacteria. The in vitro activity of cefmenoxime against Streptococcus pyogenes, Haemophilus influenzae, and Enterobacteriaceae, including indolepositive Proteus, Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii, was 10 to 1,000 times greater than that of several other cephalosporins. Against Pseudomonas aeruginosa, cefmenoxime showed activity two to four times that of sulbenicillin and carbenicillin but less than that of cefsulodin. Variation in pH, addition of horse serum, and type of growth medium had definite effects on the activity of cefmenoxime, and the inoculum size affected the activity against bacterial species. In Escherichia coli cefmenoxime showed marked affinity for penicillin-binding protein 3 (PBP-3), followed by PBP-1 (1A and 1B). This affinity profile was well correlated with its filamentous cell-forming activity under extremely low drug concentrations and with its bactericidal activity against microorganisms. The high in vitro activity of cefmenoxime was reflected in the degree of protection observed in mice infected intraperitoneally with a wide variety of gram-positive and gram-negative bacteria. Furthermore, cefmenoxime showed good therapeutic activity against infection models in mice such as respiratory tract infection caused by Klebsiellapneumoniae and urinary tract infection caused by Proteus mirabilis.
In recent years, with the increasing use of cephalosporins, an increasing number of infections caused by cephalosporin-resistant bacteria have been observed. The present report concerns the activity of cefmenoxime (SCE-1365), 7f3-[2-(2-aminothiazol-4-yl) -(Z)-2-methoxyiminoacetamido]-3-[(1-methyl-lH-tetrazol-5-yl)-thiomethyl]ceph-3-em-4-carboxylic acid ( Fig. 1 ) (10) .
Cefotiam, 7,B-[2-(2-aminothiazol-4-yl)acetamido]-3-[[1-(2-dimethylaminoethyl)-lH-tetrazol-5-yl]thiomethyl]-ceph-3-em-4-carboxylic acid (18) , is a cephalosporin with potent antibacterial activity, originally discovered and developed by Takeda Chemical Industries, Ltd., Osaka, Japan. It appears that the high antibacterial activity of cefotiam depends mainly on the aminothiazole acyl side chain at the 7-position of the cephalosporin (9) . Introduction of various substituents into the a-carbon of the acyl side chain at the 7-position of the cephalosporin resulted in cephalosporins with various properties (1, 14, 20 10 days in the case of K. pneumoniae infection; it was started at 3 days after infection and continued for 5 days in the case of P. mirabilis infection. The number of bacteria in the lung, bladder wall, kidney, and urine was determined by the method previously described (5, 7).
RESULTS
Antibacterial spectrum. Cefmenoxime exhibited a broad spectrum of antibacterial activity against various pathogenic bacterial species, including Haemophilus influenzae, indole-positive Proteus, Serratia marcescens, Citrobacter freundii, and Enterobacter cloacae. The spectrum of cefmenoxime was similar to that of cefotaxime and was wider than that of other cephalosporins.
Activity against clinical isolates. The activity of cefmenoxime against clinical isolates was compared with that of cefotaxime, cefuroxime, cefoxitin, cefmetazole, cefotiam, and cefazolin with an inoculum of 106 CFU/ml (Table 1) . Against clinical isolates of Staphylococcus aureus, the activity of cefmenoxime, resembling that of cefuroxime and cefmetazole, was greater than that of cefotaxime and cefoxitin, but the drug was less active than cefotiam and cefazolin. Against Staphylococcus epidermidis, cefmenoxime was as active as cefotaxime, more active than cefoxitin and cefmetazole, and less active than cefotiam and cefazolin. The activity of cefmenoxime against S. pyogenes and several gramnegative bacteria was similar to that of cefotaxime and was much greater than that of other cephalosporins. The MIC of cefmenoxime required to inhibit the growth of most strains was c0.025 jg/ml for H. influenzae, <0.39 ytg/ml for cefazolin-susceptible E. coli and K. pneumoniae, Proteus mirabilis, P. vulgaris, P. morganii, P.
rettgeri, and P. inconstans, <1.56 jig/ml for cefazolin-resistant E. coli and K. pneumoniae and gentamicin-susceptible S. marcescens, 6.25 ,ig/ml for gentamicin-resistant S. marcescens and E. cloacae, and 12.5 ,ug/ml for C. freundii.
The activity of cefmenoxime against these gramnegative rods was similar to that of cefotaxime and was 10 to 1,000 times greater than that of the other cephalosporins used for reference. The growth of most strains of Pseudomonas aeruginosa, P. cepacia, and P. maltophilia was inhibited at 50 jig or less of cefmenoxime per ml, and the growth of most strains of Acinetobacter calcoaceticus was inhibited by 100 ,ug/ml. The activity of cefmenoxime against P. aeruginosa was about twice that of sulbenicillin, four times that of carbenicillin, and one-eighth that of cefsulodin (data not shown).
Effect of culture medium, pH, horse serum content, and inoculum size. The MICs of cefmenoxime against some laboratory strains of gram-positive and gram-negative bacteria were determined under various conditions, and the effect of inoculum size was also studied with clinical isolates. Morphological change. The MICs of cefmenoxime against E. coli NIHJ JC-2, K. pneumoniae DT, P. rettgeri IF013501, and S. marcescens IF012648 by the agar dilution method were 0.2, 0.1, 0.0016, and 0.2 ,ug/ml, respectively, with an inoculum size of 108 CFU/ml. When these bacterial strains were exposed to a wide range of cefmenoxime concentrations from much below to well above the MICs, filamentation of organisms was observed. Lysis of the cells occurred at concentrations considerably higher than the MICs (Fig. 4) .
Affinity for PBPs. The competition of increasing concentrations of cefmenoxime for
[j4C]benzylpenicilhin binding to PBPs of E. coli KN126 was examined, and the quantitative data obtained by densitometry are summarized in Table 2 . Cefmenoxime had the highest affinity for PBP-3 and high affinities, in descending order, for PBP-1A, -1B, and -2. The affinity of cefmenoxime for PBP-4, -5, and -6 was much lower.
Protective effect. The protective effects of cefmenoxime in mice infected intraperitoneally with several strains of gram-positive and gramnegative bacteria were compared with those of cefotaxime, cefuroxime, cefoxitin, cefmetazole, cefotiam, and cefazolin (Table 3 ). In mice infected with S. aureus 308 A-1, the protective activity of cefmenoxime was greater than that of cefoxitin and similar to that of other cephalosporins. In mice infected with S. pyogenes or S. pneumoniae, cefmenoxime was much more active than other cephalosporins. In mice infected with several gram-negative bacteria, especially cefazolin-resistant strains of E. coli and K. pneumoniae, Proteus spp., S. marcescens, C. freundii, and E. cloacae, cefmenoxime was much more active than other cephalosporins. Although the MICs of cefmenoxime and cefotaxime were the same for P. morganii TN373, P.
morganii GN5278, and P. rettgeri TN338, the protective effect of cefmenoxime in mice infected with these strains was much greater than that of cefotaxime. In mice infected with other strains, cefmenoxime showed activity similar to that of cefotaxime. Although cefmenoxime showed protective activity against Pseudomonas aeruginosa and A. calcoaceticus infections, its activity was inferior to that in mice infected with other microorganisms. Effect of challenge dose.The protective effect of cefmenoxime in mice infected with various challenge doses was studied ( Recently, the functions of PBP-1, -2, and -3 as the lethal targets in E. coli have been elucidated; they are shown to be involved in peripheral cell wall expansion, cell shape determination, and septum formation, respectively (15) (16) (17) . Cefmenoxime shows remarkable affinity for these PBPs, with highest affinity for PBP-3, followed by PBP-1 (1A and 1B) and PBP-2 in E. coli KN126. This affinity profile is well reflected in the strong filamentous cell-forming activity under extremely low drug concentrations and in the comparatively low bacteriolytic activity for the drug's strong bactericidal activity. In addition, the difference in MICs of cefmenoxime, cefotiam, and cefuroxime against E. coli KN126 seems to depend upon the affinities for PBP-1, -2, and -3 in the same organism. Against S. marcescens, cefmenoxime showed bactericidal activity, but no bacteriolytic activity was observed even at very high concentrations. Study of the affmiity of cefmenoxime for PBPs of S. marcescens appears to be interesting.
The protective activity of cefmenoxime and various cephalosporins in mice infected intraperitoneally with various bacterial strains was well reflected in the in vitro antibacterial activity. In some cases, however, the protective activity did not appear to be correlated with in vitro antibacterial activity. Cefinenoxime and cefotaxime had the same MICs against P. morganii TN373 and GN5278 and P. rettgeri TN338, but the protective activity of cefmenoxime in mice infected with these organisms was greater than that of cefotaxime. Protective activities of antibiotics in mice may be influenced by the growth site of challenge organisms and by the tissue distribution and metabolism of antibiotics. In mice subcutaneously administered a single dose of 20 mg/kg, cefmenoxime and cefotaxime concentrations in plasma were almost equal but the cefmenoxime concentrations in the liver and kidney were much higher than those of cefotaxime. Furthermore, cefmenoxime was not metabolized in mice, but the major part of cefotaxime was metabolized to deacetylcefotaxime, a less active metabolite (19) . These findings suggest that P. morganii and P. rettgeri might have grown not only in the peritoneum but also in the liver and kidney.
The difference in the fate of cefmenoxime and cefotaxime in mice was also reflected in the therapeutic effect of the two cephalosporins in infection models resembling the clinical picture in humans, such as pneumonia caused by K. pneumoniae and urinary tract infection caused by P. mirabilis. The MICs of cefmenoxime and cefotaxime against K. pneumoniae DT-S were the same, whereas the cefmenoxime level in the lung was about two times higher. The therapeutic activity of cefmenoxime in Klebsiella pneumonia was about two times more potent than that of cefotaxime. In the kidney of mice given cefotaxime, only deacetylcefotaxime, not cefotaxime, was observed and the deacetylcefotaxime levels in the kidney were about one-half the cefmenoxime level. The in vitro activity of cefmenoxime against P. mirabilis IF03849 was one-half that of cefotaxime and deacetylcefotaxime. The similar therapeutic activity of the two cephalosporins in urinary tract infection caused by P. mirabilis IF03849 may be a reflection of these findings.
